TORONTO, Dec. 12 /CNW/ - Bradmer Pharmaceuticals Inc., a
biopharmaceutical company dedicated to the development and commercialization
of cancer therapies, today announced that Keith L. Black, M.D. and Roger
Stupp, M.D. have agreed to join the Company's Scientific Advisory Board. Dr.
Black is one of the leading neuro-oncology surgeons in North America, having
performed more than 5,000 operations for the resection of brain tumors, the
preliminary step in the standard of care of primary glioblastoma multiforme,
Bradmer's lead indication. Dr. Stupp's leadership role in European and
international cancer research is exemplified by his appointment as the
Chairman of the Clinical Research Division of the European Organisation for
Research and Treatment of Cancer (EORTC), and his role as lead investigator
for numerous international trials in glioblastoma multiforme.
"Dr. Black and Dr. Stupp's renowned clinical and research skills in the
study of brain cancer will provide a tremendous contribution to our Scientific
Advisory Board. Their active patient practice and frontline experience in the
treatment of glioblastoma multiforme will benefit our entire team at Bradmer,"
said Alan M. Ezrin, Ph.D., President and Chief Executive Officer of Bradmer.
"With the addition of Drs. Black and Stupp and the continued involvement
of Drs. Bigner and Zalutsky, we have secured the involvement of the preeminent
thought leaders in the study of glioblastoma multiforme from the leading brain
cancer centers in North America and Europe," added Donald W. Kufe, M.D.,
Chairman of Bradmer's Scientific Advisory Board.
Dr. Black is currently the Chairman of the Department of Neurosurgery as
well as the Director of the Comprehensive Brain Tumor Program at Cedars-Sinai
Medical Center in Los Angeles, California. He also serves as the Director of
the Maxine Dunitz Neurosurgical Institute and holds the Ruth and Lawrence
Harvey Chair in Neuroscience. Among his prior appointments, Dr. Black was the
Head of Neuro-Oncology at the UCLA Medical Center in Los Angeles. Dr. Black is
currently a member of numerous professional organizations including the
American Academy of Neurological Surgery, the Neurosurgical Society of
America, the American Association of Neurological Surgeons and the Society for
Neuro-oncology. Dr. Black has received countless awards from various academic,
community-based and media organizations which include receiving America's Top
Doctors for Cancer award, Special Recognition from the National Academy of
Science and appearing on the cover of Time magazine as part of its Heroes of
Dr. Stupp serves as a Staff Physician at the Multidisciplinary Oncology
Center (CePO) at the University Hospital in Lausanne, Switzerland (CHUV), with
special interests in the treatment of malignant brain tumors, head and neck
and lung cancer, and in particular the development of new drugs and the
association of chemotherapy and radiation. He is co-president of the
neurooncology section of the Swiss Cooperative Group for Clinical Cancer
Research, and serves as secretary of the Brain Tumor Group of the European
Association for Research and Treatment of Cancer (EORTC) and chair of the
EORTC Clinical Research Division. Dr. Stupp has chaired and published results
from recent large international randomized trials evaluating new treatments
for glioblastoma multiforme.
About Bradmer Pharmaceuticals Inc. (www.bradmerpharma.com)
Bradmer Pharmaceuticals is a biopharmaceutical company focused on the
development and commercialization of new and innovative cancer therapies.
Bradmer's lead clinical candidate, Neuradiab, was developed at Duke University
Medical Center as a proprietary therapy for a particularly aggressive form of
brain cancer, glioblastoma multiforme. To date, over US$60 million in grants
and related support has driven research and development of the licensed
treatment, which has been delivered to over 200 patients with promising
results and has completed Phase II clinical trials at Duke University. Bradmer
is currently in the process of organizing a pivotal multi-center clinical
trial of the licensed treatment. Neuradiab has been granted Orphan Drug Status
by both the U.S. Food and Drug Administration and the European Medicines
Bradmer Pharmaceuticals Inc.'s common shares have not been registered
under the Securities Act of 1933, as amended (the "Securities Act") or any
state regulatory agency in the United States. The resale or transfer by a U.S.
investor of such common shares of Bradmer Pharmaceuticals Inc. is subject to
the requirements of Rule 904 of Regulation S of the Securities Act or such
other applicable exemption thereunder, and other applicable state securities
Except for historical information, this press release may contain
forward-looking statements, which reflect the Company's current expectation
regarding future events. These forward-looking statements involve risks and
uncertainties, which may include but are not limited to, the receipt of all
regulatory approvals required to conduct the proposed clinical trial of
Neuradiab, changing market conditions, the successful and timely completion of
clinical studies, the establishment of corporate alliances, the impact of
competitive products and pricing, new product development, uncertainties
related to the regulatory approval process and other risks detailed from time
to time in the Company's ongoing quarterly and annual reporting.
For further information:
For further information: Bradmer Pharmaceuticals Inc., Mr. Brian
Brohman, Chief Business Officer, Phone: (416) 361-6058 (Ext. 804), E-mail:
firstname.lastname@example.org, Internet: www.bradmerpharma.com; Investor
Relations, Ross Marshall, The Equicom Group Inc., Phone: (416) 815-0700 (Ext.
238), Fax: (416) 815-0080, E-mail: email@example.com